How would you propose to identify and validate novel therapeutic targets for disease modification in early-stage Parkinson´s disease?

This Boehringer Ingelheim call for proposals under their OpnMe funding call asks for incoming answers to the above question accompanied by a collaboration proposal. All will be evaluated by a scientific jury, and, upon selection, chosen proposals will be pursued through a joint collaboration with the successful applicants based on mutually agreed funding terms.